PF-06424439 methanesulfonate

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2026 Feb 9;44(2):383-404.e18. [Abstract]

Customer Validation
Cells derived from in vivo PDX models were treated in vitro with DGAT2 inhibitor (DGAT2i, PF-06424439 methanesulfonate, 10μM) for 48 hours and cellular viability was measured by CellTiter-Glo assay.

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Nov 30;39(22):e71249. [Abstract]

Customer Validation
Lipid droplet accumulation was detected using Oil Red O staining. Oil Red O staining revealed that HILPDA overexpression boosted lipid droplet content in the cells, an effect that was attenuated by treatment with DGAT1 and DGAT2 inhibitors (PF‑06424439).

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 27;15(1):8273. [Abstract]

Customer Validation
Immunofluorescence images of HAECs treated with DMSO or DGAT inhibitors (A922500, 10 µM and PF-06424439, 5 µM) for 24 h, exposed to bovine serum albumin (BSA) or OA for 12 h, and then serum-starved for 48 h (n = 20 fields from 3 independent experiments). 200 µM OA was used to stimulate LD formation. BSA was used as a control treatment. Scale bar, 20 µm.

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: Mol Metab. 2024 Jun:84:101953. [Abstract]

Customer Validation
PF-06424439 methanesulfonate (10-20 μM; 24 or 48 h) inhibited the accumulation of lipid droplets during an induced ESC decidual process.

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: J Dairy Sci. 2022 Apr;105(4):3588-3600. [Abstract]

Customer Validation
The effect of DGAT1 and DGAT2 inhibitor on lipid synthesis in calf primary hepatocytes. Treatments were a control group (cells cultured in RPMI-1640 basic medium for 12 h), 1.2 mM fatty acids (cells treated with 1.2 mM fatty acids for 12 h), DGAT1 inhibitor (cells treated with 0.3 μM DGAT1 inhibitor 2 for 12 h), DGAT1 inhibitor + 1.2 mM fatty acids (cells treated with 0.3 μM DGAT1 inhibitor and 1.2 mM fatty acids for 12 h), DGAT2 inhibitor (cells treated with 0.3 μM PF-06424439 methanesulfonate (DGAT2 inhibitor) for 12 h), DGAT2 inhibitor + 1.2 mM fatty acids (cells treated with 0.3 μM PF-06424439 methanesulfonate and 1.2 mM fatty acids for 12 h). Representative western blots of SREBF1, FASN, DGAT1, DGAT2, MTTP, and APOB.

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: J Dairy Sci. 2022 Apr;105(4):3588-3600. [Abstract]

Customer Validation
The effect of the DGAT1 and DGAT2 inhibitors on immunofluorescence of lipid droplets in calf primary hepatocytes. Treatments were control group (cells cultured in RPMI-1640 basic medium for 12 h), 1.2 mM fatty acids (cells treated with 1.2 mM fatty acids for 12 h), DGAT1 inhibitor (cells treated with 0.3 μM DGAT1 inhibitor 2 for 12 h), DGAT1 inhibitor + 1.2 mM fatty acids (cells treated with 0.3 μM DGAT1 inhibitor 2 and 1.2 mM fatty acids for 12 h), DGAT2 inhibitor (cells treated with 0.3 μM PF-06424439 methanesulfonate (DGAT2i) for 12 h), and DGAT2 inhibitor + 1.2 mM fatty acids (cells treated with 0.3 μM PF-06424439 methanesulfonate and 1.2 mM fatty acids for 12 h).

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: J Virol. 2022 Jan 26;96(2):e0147321. [Abstract]

Customer Validation
N2a cells were incubated with DGAT1 inhibitor (DGAT1i) (A922500, 10 μg/mL), DGAT2i (PF-06424439 methanesulfonate, 40 μg/mL), or a combination (A922500 plus PF-06424439 methanesulfonate) for 48 h, and cell viability was assessed by a Cell Counting kit-8 (CCK-8) assay (n = 3).

PF-06424439 methanesulfonate purchased from MedChemExpress. Usage Cited in: Dev Comp Immunol. 2021 Nov:124:104197. [Abstract]

Customer Validation
After preincubation with 30 μM DGAT1 inhibitor or 40 μM DGAT2 inhibitor (PF-06424439) for 1 h, CIK cells were treated with 3 μM Gardiquimod for 24 h. mRNA expression of DGAT1 and DGAT2 in CIK cells.